Januvia, which is the brand name version of sitagliptin, is a once-a-day medication sold by Merck for the treatment of type-2 diabetes. Introduced in 2006, it has become one of the best selling diabetes drugs in the world, with use in over 80 countries.
Unfortunately, the FDA, American Medical Association and researchers at UCLA have issued a Januvia warning in recent years linking the drug to increased risks of pancreatic cancer or thyroid cancer.
Januvia can lower blood-sugar levels in people with diabetes by inhibiting the enzyme DPP-4, which is a natural barrier to insulin creation. This increases insulin production and the absorption of sugar from the blood. However, DPP-4 may also prevent the spread of cancerous cells, meaning Januvia may reduce the body’s natural protection against cancer.
The FDA first issued a Januvia warning in 2009 after receiving more AERS adverse event reports than expected showing patients were developing pancreatitis while taking the drug. At that time, they forced Merck to add label warnings for pancreatitis.
However, Merck has not issued a Januvia warning advising consumers of the risk of pancreatic cancer or thyroid cancer. Due to their failure to properly warn patients of these risks, they face liability for the damages.
If you or a loved one have been diagnosed with pancreatic cancer or thyroid cancer after taking Januvia, it is important to speak with a lawyer about your legal rights as soon as possible. You may be entitled to substantial compensation. Contact us today.
Records show that even after warnings from experts that Januvia may be associated with pancreatic or thyroid cancer, Merck has continued making billions each year selling the drug without proper warning, and has delayed important testing ordered by the FDA.
In 2011, researchers from the University of California at Los Angeles published a study suggesting drugs like Januvia could increase the risk of pancreatic cancer by 270% and thyroid cancer by 148%.
Due to increased safety concerns, the FDA ordered Merck to conduct a new 3-month study of Januvia all the way back in 2009. Although they agreed to comply in 2010 and 2011, an FDA violation notice in 2012 indicated Merck was still delaying the tests.
The most recent Januvia warning came in February of 2013, when the Journal for the American Medical Association published a study showing drugs like Januvia could double the risk for pancreatitis, which can lead to pancreatic cancer. The FDA then issued a new warning in March of 2013.
If you or a family member have been affected by pancreatic cancer or thyroid cancer, it is important to speak with a lawyer to learn what help is available and how long you have to take action.
Lawsuits for defective drug injuries can be very complex. Therefore, it is important to choose a lawyer with experience in this type of case. DrugRisk only recommends lawyers and law firms that have already handled diabetes drug cancer lawsuits or Januvia lawsuits.
Contact us today for more information on the warnings, research, side effects and legal news related to Januvia and other diabetes drugs, or to speak with a lawyer. We are available 24 hours a day to help.